Month: May 2023
– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date – – Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date – – Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the…
Read More
Excerpt from the Press Release: NATICK, Mass. and QUINCY, Mass., April 26, 2023 /PRNewswire/ — Avenge Bio, Inc. (“Avenge”), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the successful completion of the first dose cohort in a Phase…
Read More
Excerpt from the Press Release: BOSTON, April 27, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has received written approval from the Dana Farber Cancer Institute Institutional Review Board (IRB) to proceed with its…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif., April 27, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced positive interim clinical data from the Phase 1 Dose Exploration stage (three doses, n=15) of the 4D-150…
Read More
Baptist Health Cancer Care Abstract to be presented at Oncology Nursing Society Annual Symposium Excerpt from the Press Release: NORWOOD, Mass., April 27, 2023 /PRNewswire/ — Entrinsic Bioscience is pleased to announce the upcoming poster session on the role of Enterade® Advanced Oncology Formula in reducing adverse gastrointestinal side effects for patients undergoing cancer treatment. The…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the first patient has been dosed at City of Hope…
Read More- « Previous
- 1
- 2
- 3